Mutations in an enzyme involved in protein degradation affect a signaling pathway that stimulates the development of the digestive tract.
DNA sequencing has been very successful in identifying mutations associated with human genetic disorders, but understanding how the disruption of particular genes results in disease remains a constant challenge. One such example of this is the identification of mutations in a gene known as NGLY1 in patients with an inherited disorder (Need et al., 2012). NGLY1 encodes an enzyme that is found in the cytoplasm of all cells and is responsible for removing sugar chains known as N-glycans from proteins that are destined to be degraded (Figure 1A; Suzuki et al., 1993; Suzuki et al., 2016). Patients harboring mutations in this gene present with a multitude of symptoms, including delayed development, peripheral nerve disorders and low muscle tone (Enns et al., 2014; Caglayan et al., 2015; Lam et al., 2017). However, it is not clear how the loss of this enzyme leads to these symptoms.
Now, in eLife, Hamad Jafar-Nejad and colleagues at Baylor College of Medicine and the RIKEN Global Research Cluster – including Antonio Galeone as first author – report new insights into the role of this enzyme in the development of the fruit fly, Drosophila melanogaster (Galeone et al., 2017). Fruit flies have served as excellent models for studying many aspects of human development and disease over the years. Taking advantage of sophisticated genetic tools unique to the fly, Galeone et al. show that the loss of a gene called Pngl – which is the fruit fly equivalent of NGLY1 – causes portions of the digestive tract to be malformed. Further experiments trace these defects back to when the digestive tract begins to form in the embryo and reveal that a signaling pathway known as bone morphogenetic protein (or BMP) signaling is disrupted in cells that will give rise to portions of the digestive tract.
The BMP pathway is of particular interest because it regulates many aspects of development in both fruit flies and mammals (Wang et al., 2014). Cells secrete molecules known as BMP ligands that then bind to specific receptors on the surface of cells to stimulate BMP signaling cascades (O'Connor et al., 2006). BMP ligands exist as dimers containing either two identical ligand molecules (homodimers) or two different ones (heterodimers). Galeone et al. demonstrate that a BMP ligand called Dpp forms fewer homodimers in the developing gut of flies with mutations in Pngl. This leads to defects in BMP signaling in two layers of tissue that are required for the digestive system to form properly (Figure 1B).
This study is the first to identify a specific signaling pathway that is disrupted in the absence of the Pngl enzyme and may provide insight into the underlying causes of some of the symptoms typically seen in patients with mutations in the NGLY1 gene. Whether patients have similar alterations in BMP signaling within specific cells or tissues remains to be determined, but this study will help to inform future investigations.
The findings of Galeone et al. raise a number of questions regarding how this enzyme works. An enzymatically inactive version of Pngl did not rescue specific digestive system defects, suggesting that Pngl activity is important for BMP signaling. However, it is not known whether the enzyme acts directly on Dpp to affect its ability to form homodimers. It is also possible that the loss of Pngl could affect BMP signaling indirectly, by influencing how other proteins within these cells are modified or degraded. BMP signaling within the affected cells may be uniquely sensitive to disruptions in the normal systems that regulate proteins at this stage of development. Additionally, not all phenotypes within the Pngl mutants are due to defects in BMP signaling, suggesting that the Pngl enzyme also affects other proteins and pathways. Direct examination of the N-glycans attached to Dpp and other proteins in wild type and Pngl-deficient tissues will begin to address some of these questions.
Finally, studies on the role of NGLY1 in other organisms suggest that this enzyme may have roles beyond the removal of N-glycans on proteins destined for degradation (Dalet et al., 2011; Figure 1A). There is also evidence suggesting NGLY1 has a role in cells that is independent of its enzymatic activity (Maerz et al., 2010). Regardless, the study by Galeone et al. demonstrates that loss of Pngl results in tissue- and stage-specific alterations in the BMP signaling pathway and provides a new lens through which we can begin to dissect how it influences other systems.
NGLY1 mutation causes neuromotor impairment, intellectual disability, and neuropathyEuropean Journal of Medical Genetics 58:39–43.https://doi.org/10.1016/j.ejmg.2014.08.008
Prospective phenotyping of NGLY1-CDDG, the first congenital disorder of deglycosylationGenetics in Medicine 19:160–168.https://doi.org/10.1038/gim.2016.75
The Neurospora peptide:N-glycanase ortholog PNG1 is essential for cell polarity despite its lack of enzymatic activityJournal of Biological Chemistry 285:2326–2332.https://doi.org/10.1074/jbc.M109.045302
Clinical application of exome sequencing in undiagnosed genetic conditionsJournal of Medical Genetics 49:353–361.https://doi.org/10.1136/jmedgenet-2012-100819
Identification of peptide:N-glycanase activity in mammalian-derived cultured cellsBiochemical and Biophysical Research Communications 194:1124–1130.https://doi.org/10.1006/bbrc.1993.1938
- Version of Record published: September 14, 2017 (version 1)
This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.
Downloads (link to download the article as PDF)
Download citations (links to download the citations from this article in formats compatible with various reference manager tools)
Open citations (links to open the citations from this article in various online reference manager services)
Growth plate and articular cartilage constitute a single anatomical entity early in development but later separate into two distinct structures by the secondary ossification center (SOC). The reason for such separation remains unknown. We found that evolutionarily SOC appears in animals conquering the land - amniotes. Analysis of the ossification pattern in mammals with specialized extremities (whales, bats, jerboa) revealed that SOC development correlates with the extent of mechanical loads. Mathematical modeling revealed that SOC reduces mechanical stress within the growth plate. Functional experiments revealed the high vulnerability of hypertrophic chondrocytes to mechanical stress and showed that SOC protects these cells from apoptosis caused by extensive loading. Atomic force microscopy showed that hypertrophic chondrocytes are the least mechanically stiff cells within the growth plate. Altogether, these findings suggest that SOC has evolved to protect the hypertrophic chondrocytes from the high mechanical stress encountered in the terrestrial environment.
Erythropoietin (EPO) is a key regulator of erythropoiesis. The embryonic liver is the main site of erythropoietin synthesis, after which the kidney takes over. The adult liver retains the ability to express EPO, and we discovered here new players of this transcription, distinct from the classical hypoxia-inducible factor pathway. In mice genetically-invalidated in hepatocytes for the chromatin remodeler Arid1a, and for Apc, the major silencer of Wnt pathway, chromatin was more accessible and histone marks turned into active ones at the Epo downstream enhancer. Activating β-catenin signaling increased binding of Tcf4/β-catenin complex and upregulated its enhancer function. The loss of Arid1a together with β-catenin signaling, resulted in cell-autonomous EPO transcription in mouse and human hepatocytes. In mice with Apc-Arid1a gene invalidations in single hepatocytes, Epo de novo synthesis led to its secretion, to splenic erythropoiesis and to dramatic erythrocytosis. Thus, we identified new hepatic EPO regulation mechanism stimulating erythropoiesis.